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Urinary bladder cancer is the 7th most common cancer in Western Europe (Ferlay et al., 
2012). The most relevant risk factors are occupational exposure to aromatic amines and poly-
cyclic aromatic hydrocarbons as well as cigarette smoking (Golka et al., 2012, 2009, 2004; 
Schwender et al., 2012). Moreover, polymorphisms of phase II metabolizing enzymes are 
well-known since decades to increase bladder cancer risk, in particular, the deletion variant of 
the phase II metabolizing enzyme glutathione-S-transferase M1 (GSTM1) (Ovsiannikov et al., 
2012; Golka et al., 2009, 1997; Arand et al., 1996) and polymorphisms in the N-
acetyltranferase 2 (NAT2) gene leading to a reduced acetylation capacity (Selinski et al., 
2011; Moore et al., 2011; Golka et al., 2002, 1996), and currently their influence on prognosis 
is investigated (Roth et al., 2012; Nørskov et al., 2011). Recently, genome-wide association 
studies (GWAS) have identified several novel nucleotide polymorphisms (SNPs) as associat-
ed with urinary bladder cancer (UBC) risk and most of them could be confirmed in independ-
ent follow-up case-control series (review: Golka et al., 2011; Table 1). So far SNPs at ten 
chromosomal locations, besides GSTM1, have been identified. The functions of the closest 
genes are related to maintenance of DNA integrity, apoptosis and cell cycle control as well as 
detoxification of carcinogens. Considering the large size of the case-control series with more 
than 4,500 cases and 45,000 controls (Rafnar et al., 2011; Kiemeney et al., 2010; Rothman et 
al., 2010), the high density of polymorphisms on SNP chips as well as the accuracy of SNP 
imputation algorithms it may be regarded as likely that the most influential SNPs have now 
been discovered. However, one open question remains: to date it is completely unknown, if 
the novel SNPs interact. If so, will they result in less than additive, additive or even over addi-
tive risks? How high is the population attributable risk of the combined influence of all poly-
morphisms? And how important is the combined genetic risk compared to the risk attributable 
to cigarette smoking and occupational exposure to bladder carcinogens? Considering the re-
cent progress in genome-wide association studies it can be expected that answers to these 
questions will soon be available.  
 
First analyses beyond the standard single SNP analyses in case-control designs yield promis-
ing results (Binder et al., 2012; Menashe et al., 2012; Schwender et al., 2012).  
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Table 1: Currently confirmed genetic variants that are associated with bladder cancer risk. Polymor-
phisms and related genes are printed bold, risk alleles are given in brackets. 
Key message Reference 
 
Rs9642880[T] near proto-oncogene MYC (v-myc myelocytomatosis 
viral oncogene homolog (avian) was associated with UBC in a GWAS 
(OR=1.22). 
Kiemeney et al., 2008 
The effect of rs9642880[T] was less pronounced in cases with sus-
pected exposure to bladder carcinogens (OR=1.04 and 1.11 exposed 
study groups; OR=1.36 non-exposed) for which GSTM1 null is the 
more important genetic risk factor (OR=2.43 and 1.38 exposed; 
OR=1.22 non-exposed). 
Golka et al., 2009 
Rs710521[A] near the TP63 (tumor protein 63) gene, that encodes 
for a member of the p53 family of transcription factors, was associat-
ed with UBC in a GWAS (OR=1.19). 
Kiemeney et al., 2008 
The effect of rs710521[A] on UBC risk (OR=1.16) did not depend on 
exposure to bladder carcinogens via tobacco smoke or occupation.  
Lehmann et al., 2010 
Rs401681[C] in an intron of CLPTM1L (cisplatin resistance related 
protein CRR9p) and the nearby synonymous rs2736098[A] in the 2nd 
exon of TERT (telomerase reverse transcription) were both associat-
ed with UBC in a GWAS (OR=1.12; OR=1.16). The CLPTM1L gene 
associated with cisplatin-induced apoptosis and the nearby TERT that 
is involved in telomere maintenance and thus in aging are located at 
a potential cancer susceptibility locus at 5p15.33. 
Rafnar et al., 2009 
Rs2294008[T] alters the start codon of PSCA (prostate stem cell an-
tigen) leading to a reduced promoter activity in vitro and was associ-
ated with UBC in a GWAS (OR=1.15). PSCA is over-expressed in 
prostate and bladder tumors. 
Wu et al., 2009 
Rs2978974[A] in an alternative untranslated 1st exon of PSCA was 
associated with UBC in a fine-mapping study (OR=1.11) and interact-
ed with rs2294008 10 kb upstream rs2978974.  
Fu et al., 2012 
Rs798766[T] in an intron of TACC3 (transforming, acidic coiled-coil 
containing protein 3), 70 kb of FGFR3 (fibroblast growth factor recep-
tor 3) was associated with UBC in a GWAS (OR=1.24).  
Kiemeney et al., 2010 
Rs11892031[C] in an intronic region in the UGT1A (UDP glucu-
ronosyltransferase 1 family, polypeptide A complex locus) cluster was 
associated with UBC in a GWAS (OR=0.84) showing a protective ef-
fect of the minor allele [C]. UGT1A proteins are involved in the me-
tabolisms of bladder carcinogens via glucuronidation. 
Rothman et al., 2010 
Rs11892031[C] showed a more pronounced protective effect in per-
sons with occupational exposure to polycyclic aromatic hydrocarbons 
and aromatic amines (OR=0.68 exposed; OR=0.83 all combined).  
Selinski et al., 2012 
Rs17863783[T] a synonymous rare (2 %) SNP in a UGT1A6 exon 
was shown to increase UGT1A6.1 mRNA expression in vitro and was 
associated with UBC in a fine-mapping study (OR=0.55). 
Rs17863783 explained most of the effect of rs11892031. 
Tang et al., 2012 
Rs1495741[A] a tagSNP for NAT2 (N-acetyltransferase 2) activity, 14 
kb 3' of NAT2, was associated with UBC in a GWAS (ORA/A=1.15). 
Polymorphisms of NAT2 lead to a reduced acetylation of drugs and 
xenobiotics (“slow” and “rapid” acetylators) and are a well-known risk 
factor for UBC. The A/A genotype tags the slow phenotype. Increased 
risks were observed in current smokers (OR=1.25). 
Rothman et al., 2010 
NAT2 tagSNP rs1495741[A/A] showed an excellent specificity (0.94) 
regarding the phenotype but was outperformed by the common NAT2 
genotype (1.00) and a 2-SNP genotype (1.00) based on the known 
NAT2 SNPs in Caucasians.  
Selinski et al., 2011 
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Table 1 (cont.): Currently confirmed genetic variants that are associated with bladder cancer risk.  
Polymorphisms and related genes are printed bold, risk alleles are given in brackets. 
Key message Reference 
 
Rs8102137[C] near CCNE1 (cyclin E1) involved in the cell cycle 
G1/S phase transition was associated with UBC in a GWAS 
(OR=1.13). CCNE1 over-expression seems to be associated with tu-
morigenesis and UBC prognosis.  
Rothman et al., 2010 
Rs1014971[T] 25 kb from CBX6 (chromobox homolog 6) and 64 kb 
from APOBEC3A (apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3A) was associated with UBC in a GWAS (OR=1.14). 
Rothman et al., 2010 
The well-known increased UBC risk of GSTM1 null genotypes was 
confirmed in a GWAS (OR=1.47). 
Rothman et al., 2010 
Rs1058396[G] in SLC14A1 (solute carrier family 14 (urea trans-
porter), member 1 (Kidd blood group)) exon 8 leading to an amino 
acid exchange and rs17674580[T] in an intron of the same gene are 
associated with UBC in a GWAS (OR=1.14; OR=1.17). SLC14A1 is 
involved in maintenance of a constant urea concentration gradient in 
the kidney. Rs1058396 (D280N) determines two alleles of the Kidd 
blood system. Rs17674580 explained the effect of rs1058396. 
Rafnar et al., 2011 
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